EPIC Program Annual Report 2009-2010 Appendix: Table VIII
| Rank by Number of Claims | Drug and Strength | Drug Type** | Number of Claims | EPIC Payments | Rank by Payment |
|---|---|---|---|---|---|
| Top 20 Totals | 1,896,413 | $51,103,622 | |||
| Percent of Top 20 Drugs to Total Paid Claims | 19.59% | 15.32% | |||
| 1 | PLAVIX (75 MG) | SS | 181,987 | $16,461,902 | 1 |
| 2 | OMEPRAZOLE (20 MG) | Gen | 145,822 | $884,924 | 73 |
| 3 | FUROSEMIDE (40 MG) | Gen | 120,316 | $162,930 | 335 |
| 4 | AMLODIPINE BESYLATE (5 MG) | Gen | 115,009 | $321,830 | 190 |
| 5 | SIMVASTATIN (20 MG) | Gen | 103,689 | $337,175 | 178 |
| 6 | NEXIUM (40 MG) | SS | 100,355 | $10,870,410 | 2 |
| 7 | ALENDRONATE SODIUM (70 MG) | Gen | 98,604 | $471,405 | 126 |
| 8 | SIMVASTATIN (40 MG) | Gen | 97,186 | $356,924 | 169 |
| 9 | FUROSEMIDE (20 MG) | Gen | 95,915 | $103,822 | 487 |
| 10 | AMLODIPINE BESYLATE (10 MG) | Gen | 90,192 | $262,404 | 228 |
| 11 | LIPITOR (10 MG) | SS | 86,309 | $4,838,255 | 6 |
| 12 | HYDROCHLOROTHIAZIDE (25 MG) | Gen | 83,901 | $44,500 | 812 |
| 13 | METOPROLOL TARTRATE (50 MG) | Gen | 81,901 | $134,061 | 404 |
| 14 | SPIRIVA (18MCG) | SS | 81,414 | $6,293,418 | 4 |
| 15 | METFORMIN HCL (500 MG) | Gen | 75,581 | $206,830 | 270 |
| 16 | LIPITOR (20 MG) | SS | 74,356 | $5,891,217 | 5 |
| 17 | METOPROLOL SUCCINATE (50 MG) | Gen | 71,530 | $860,575 | 78 |
| 18 | METOPROLOL TARTRATE (25 MG) | Gen | 69,885 | $118,262 | 449 |
| 19 | ATENOLOL (50 MG) | Gen | 62,354 | $88,661 | 527 |
| 20 | XALATAN (0.005%) | SS | 60,107 | $2,394,117 | 21 |
* Table VIII lists the top 20 drugs ranked by number of adjudicated claims for the program year (October 2009-September 2010) as well as the percentage of the total claims they represent for the year.
** Drug Type values are BNMS='Brand Name Multi-Source', Gen='Generic' and SS='Sole Source.'
